UNITED STATES

SECU	RITIES AND EXCHANGE COMMIS Washington, DC 20549	SION
	FORM 8-K	
	CURRENT REPORT	
	Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934	
Date	August 12, 2021 of Report (date of earliest event report	rted)
(Exact 1	OpGen, Inc. name of Registrant as specified in its c	harter)
Delaware (State or other jurisdiction of incorporation or organization)	001-37367 (Commission File Number)	06-1614015 (I.R.S. Employer Identification Number)
(Addı	9717 Key West Ave, Suite 100 Rockville, MD 20850 ress of principal executive offices)(Zip	code)
(Registr	(240) 813-1260 rant's telephone number, including are	a code)
(Former nar	ne or former address, if changed since	last report)
Check the appropriate box below if the Form 8-K filing following provisions (see General Instruction A.2. below)		the filing obligation of the registrant under any of the
[_] Written communications pursuant to Rule 425 under the		
[_] Soliciting material pursuant to Rule 14a-12 under the I	Exchange Act (17 CFR 240.14a-12)	
[_] Pre-commencement communications pursuant to Rule	14d-2(b) under the Exchange Act (17 C	FR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule	13e-4(c) under the Exchange Act (17 Cl	FR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:		
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	OPGN	The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerg chapter) or Rule 12b-2 of the Securities Exchange Act of 1		405 of the Securities Act of 1933 (§230.405 of this
Emerging growth company \square		
If an emerging growth company, indicate by check mark is or revised financial accounting standards provided pursuant		

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2021, OpGen, Inc. (the "Company") issued a press release announcing its second quarter financial results for the quarter ended June 30, 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press Release, dated August 12, 2021.
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information included in Item 2.02 herein and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 12, 2021 **OpGen, Inc.**

By: /s/ Timothy C. Dec

Name: Timothy C. Dec

Title: Chief Financial Officer



OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update

- · Total Revenue for Q2 2021 was approximately \$0.8 million
- · Cash as of June 30, 2021 was approximately \$31.2 million, up significantly from the \$13.4 million at year-end 2020

Conference call to be held at 4:30 p.m. Eastern Daylight Savings Time today

ROCKVILLE, Md., August 12, 2021 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, "OpGen"), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its financial and operating results for the three and six months ended June 30, 2021 and provided a business update. Total OpGen revenue for the second quarter of 2021 was approximately \$0.8 million, down 32% from \$1.2 million in the second quarter of 2020. Cash as of June 30, 2021 was approximately \$31.2 million, up significantly from the \$13.4 million at year-end 2020.

Oliver Schacht, President & CEO of OpGen, commented, "We are continuing to execute on our key development milestones as recently seen with our assembly of 10 final pre-series release analyzers of the Unyvero A30 *RQ* platform. In this growth-oriented quarter we presented key clinical data at several conferences, provided an update to our robust R&D pipeline, and successfully completed a move to our new corporate headquarters. I am pleased with our accomplishments and continue to believe we are putting our company in a position to succeed."

Second Quarter 2021 Financial Results of OpGen, Inc.

- Total revenue for the second quarter of 2021 was approximately \$0.8 million, down 32% from \$1.2 million in the second quarter of 2020. This decrease is primarily attributable to exiting the FISH business at the end of the first quarter of 2021 as well as the conclusion of non-recurring partnering revenues from a completed R&D collaboration at Ares Genetics in 2020. Total revenue for the first half of 2021 was approximately \$1.6 million, as compared to \$1.8 million for the first half of 2020. This decrease is primarily attributable to a decline of \$0.4 million in revenue due to our exit from the FISH business and a decline of \$0.5 million in revenue due to the conclusion of non-recurring partnering revenues from a completed R&D collaboration at Ares Genetics in 2020 offset by an increase in lab service revenue of \$0.4 million and a \$0.3 million increase in Unyvero product revenue.
- Operating expenses for the second quarter of 2021 were approximately \$7.0 million compared with \$7.7 million in the second quarter of 2020. Operating expenses for the first half of 2021 were approximately \$14.0 million, as compared to \$12.3 million for the first half of 2020.
- The net loss for the second quarter of 2021 was \$7.1 million, or \$0.19 per share, compared with \$7.5 million, or \$0.49 per share, in the second quarter of 2020. The net loss for the first half of 2021 was \$21.9 million, or \$0.65 per share, as compared with a net loss of \$11.4 million, or \$1.00 per share, for the first half of 2020;
- · Cash and cash equivalents were \$31.2 million as of June 30, 2021 compared to \$13.4 million as of December 31, 2020.

The company announced accomplishment of the following key milestones and recent developments in the second quarter as well as 2021 to date:

- · Curetis, an OpGen subsidiary, successfully achieved a key development milestone by completing the assembly of 10 final pre-series release Unyvero A30 *RQ* analyzers. The systems have now commenced final verification and validation testing. The Unyvero A30 *RQ* platform can be made available to third party development and commercialization partners and licensees for their own assay menu and product portfolio. Discussions are currently ongoing with several potential platform partners for various content-and-licensing or partnering scopes.
- OpGen submitted an updated 510(k) summary to the FDA for our Acuitas AMR Gene Panel for Isolates in June 2021. We believe the FDA has provided substantive feedback on all key documents, including the Package Insert, Electronic User Guide, and Operator Manual in May. The FDA previously stated that they expect to complete its review by the end of August 2021. Since such communications, there have been no changes to the timeline, and the FDA has not provided any additional requests or questions. The FDA previously clarified that their timelines can be affected by various factors including the FDA's other workload and public health priorities. Although the FDA has not committed to a timeline, we currently expect to see a completed review based on this timeline.
- OpGen completed the move of its U.S. headquarters, labs, and operations to a new facility in Rockville, Maryland. The 10,000 square foot facility results in net savings of approximately \$0.6 million annually in operating efficiencies and reduced rent. Going forward, all Unyvero cartridges, as well as Acuitas consumables, will be stocked and shipped directly from the new Rockville-based facility.
- OpGen announced prospective clinical data on the Unyvero LRT BAL at the June 29, 2021 webinar titled "One Academic Medical Center's Experience with the Unyvero Multiplex Platform for Testing Bronchoalveolar Lavage Fluids: Analytical and Clinical Assessment", which studied patients in the intensive care unit for whom bronchoalveolar lavage (BAL) specimen was ordered for diagnostic purpose and prospectively evaluated with the Unyvero LRT BAL panel in conjunction with quantitative bacterial culture and antimicrobial susceptibility testing. The clinical impact of the Unyvero results on antibiotic stewardship and patient management were discussed and acted upon in real-time, enabling earlier adjustment of antimicrobial therapy in 53% of cases.
- Dr. Cory Hale, Infectious Disease Clinical Pharmacist at the Penn State Health Milton S. Hershey Medical Center, presented on Unyvero LRT at the virtual World Microbe Forum 2021. In their talk titled "Antimicrobial Stewardship Opportunities Using Results from a Multiplex Molecular Lower Respiratory Tract Panel as Compared to Conventional Culture", their data characterized the potential impact of Unyvero LRT on antibiotic therapy in patients being treated for pneumonia. Retrospective chart reviews were performed in 92 of these patients, including 51 critically ill ICU patients and 39 pediatric patients. They reported complete agreement between Unyvero LRT and culture results in 50% of cases, and in 45.7% of cases, Unyvero yielded more information than culture. This demonstrates the potential value that Unyvero LRT could bring in clinical patient management.

- · An 'i-poster' presented at the virtual World Microbe Forum 2021 by Dr. Drew Bell of Indiana University School of Medicine, titled "Clinical Evaluation of a Multiplex Molecular Diagnostic Lower Respiratory Tract Panel for Bronchoalveolar Lavage Specimens," demonstrated that the Unyvero LRT BAL provided a basis for appropriate escalation and de-escalation of antibiotic therapies in 42% of cases, reducing time to appropriate therapy by 31 hours.
- Ares Genetics, an OpGen subsidiary, recently entered into several additional collaborations that are expected to help expand the ARESdb as a curated AMR marker database. These additional collaborations include on the one hand, a scientific and clinical project with UPMC, Pittsburgh, PA and on the other hand a strategic collaboration with a leading U.S. CRO and reference lab. Under the latter collaboration agreement Ares Genetics will be able to select a large number of clinical isolates to augment and grow its unique ARESdb with curated data sets. In return Ares has committed to providing certain next generation sequencing (NGS) services to the collaboration partner. Several additional collaboration and licensing agreements are currently in various stages of negotiation and pricing discussions.
- Dr. Johannes Weinberger, NGS Lab Director at Ares Genetics provided an update on their culture-free genomic assay for AMR surveillance via virtual presentation at a conference sponsored by Twist Bioscience. Dr. Weinberger commented that "The sensitivity for AMR marker detection in native urine samples from septic patients with confirmed mono-infections in our study was determined to be between 94% and 100% when compared to comparator data obtained from whole genome sequencing of the corresponding bacterial isolate."
- Dr. Arne Materna, CEO of Ares Genetics, presented virtually at the Genomics-Track discussion at the Amazon Web Services healthcare & life sciences symposium. Dr. Materna discussed that the Ares universal pathogenome assay (ARESupa), is currently being evaluated in a paid-for early access program for which Ares has already signed up five public health organizations from different European countries.
- Dr. Materna presented preliminary data of an ongoing, multicenter validation of long-read nanopore sequencing of clinical isolates through two virtual seminars, furthering OpGen's R&D updates. Ares Genetics is conducting the multicenter validation by Oxford Nanopore Technology (ONT) in combination with AREScloud for data analysis. AREScloud assisted conversion of ONT data into clinically and epidemiologically relevant information proved highly accurate for participating labs, with consistent average accuracies of 100% for pathogen identification, up to 97% for AMR marker detection, and up to 100% for predictive antimicrobial susceptibility testing (AST).

Mr. Schacht commented, "As we continue into the third quarter, we are waiting for the FDA to complete their review of our AMR Gene Panel for Isolates. We are also in regular dialog with the Chinese NMPA via our strategic partner Beijing Clear Bio. The Chinese NMPA recently requested supplemental clinical data to be generated and submitted in China, and we are working with our partners to finalize study design and swift study execution in due course. We are also working diligently on finding a new Chief Financial Officer to join the OpGen team following the resignation of our current CFO Tim Dec. Together with our board, we are continuing to evaluate alternatives for financing the future growth of OpGen and believe these are steps that will help drive the company forward and on its desired path."

Conference Call Information

OpGen's management will host a conference call today, August 12 at 4:30 p.m. EDT to discuss the second quarter financial results and other business activities, as well as answer questions. Dial-in information is below:

Dial-in Information

U.S. Dial-in Number: +1-800-458-4121 International Dial-in Number: +1-323-794-2093

Webcast: http://public.viavid.com/index.php?id=146054

Conference ID: 7301173

Following the conclusion of the conference call, a replay will be available through August 26, 2021. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company's website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company's website for 90 days. Replay access information is below:

Replay Information

U.S. Dial-in Number: +1-844-512-2921 International Dial-in Number: +1-412-317-6671

Replay PIN: 7301173

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen's product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding OpGen's second quarter and first half of 2021 results and the current business of OpGen. These statements and other statements regarding OpGen's future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from our financings, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company's operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new

OpGen, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (unaudited)

Cash and cash equivalents \$ 31,18,285 \$ 13,36,0,485 Accounts receivable, net 472,567 65,3 (10) Inventory, net 1,333,800 1,485,986 Prepai de spenses and other current assets 35,070,381 1,886,986 Property and equipment, net 227,209 449,628 Operating less right-of-use assets, net 277,09 480,628 Operating less right-of-use assets 27,00,955 8,024,729 Intangible assets, net 15,662,234 16,580,933 Order noncurrent assets 555,100 7,709,955 Other noncurrent assets 555,100 7,709,955 That age in inventory 2,500,000 1,500,000 Total Circumstory 5,500,000 1,500,000 Total Circumstry 1,500,000 1,500,000 Accrued Company and properties an		 June 30, 2021	December 31, 2020
Cash and cash equivalents \$ 31,18,285 \$ 13,36,0,485 Accounts receivable, net 472,567 65,3 (10) Inventory, net 1,333,800 1,485,986 Prepai de spenses and other current assets 35,070,381 1,838,096 Probal current assets 35,070,381 3,589,487 Probat que quipment, net 27,209 449,688 Operating less right-of-use assets, net 277,09 58,042,729 Intangible assets, net 7,790,595 8,042,729 Intangible assets, net 1,566,234 1,580,933 Vice product assets 2,953,409 1,780,955 Total current assets 5,553,600 1,780,955 Vice product assets 2,953,600 1,780,955 Vice product assets 5,553,600 1,880,400 Total current assets 9,553,600 1,880,400 Total current assets 1,207,113 1,868,666 Total current assets 1,207,113 1,868,666 Accrued compensation and benefits 1,541,869 1,451,469 Accrued compensation and benefits 1,542,400	<u>Assets</u>		
Accounts receivable, net 45.30.80 5.81.04 Inventory, net 1.33.80 1.38.080 Prepaid expenses and other current assets 2081,549 1.38.000 Total current assets 42.21,555 3.58.000 Property and equipment, net 4.223,155 3.59.947 Finance lease right-of-use assets, net 2.03.007 2.02,200 Operating lease right-of-use assets 2.03.007 8.02,209 Gowall 7.790,595 8.02,279 Istangible assets, net 1.560,2324 1.580,600 Strategic inventory 2.995,465 1.790,505 Total sace 5.555,109 7.799,505 Strategic inventory 5.555,109 7.799,505 Total sace 5.20,501 7.20,500 Accounts passed sace 1.20,711 \$ 1.686,666 Accountial sace 6.90,000	Current assets		
Inventory, net 1,333,80 1,858,966 Prepaid expenses and other current assets 2,000,90 1,808,000 Total current assets 3,000,81 1,808,000 Property and equipment, net 422,205 43,259,487 Chance lease right-of-use assets, net 207,000 40,000 Operating lease right-of-use assets 2,008,000 20,000 Good will 1,566,224 16,560,234 16,509,000 Untargible assets, net 1,566,234 16,509,000 16,500,200 17,90,505 16,509,000 Other noncurrent assets 5,551,00 77,90,505 17,90,505 17,90,505 18,606,605 18,000,000 1	Cash and cash equivalents	\$ 31,182,385	\$ 13,360,463
Prepail expenses and other current assets 2,081,50 1,380,00 Total current assets 350,70,31 1,680,70 Property and equipment, net 4,223,15 3,259,487 Finance lease right-of-use assets. 2,203,00 3,208,200 Operating lease right-of-use assets 2,030,00 3,00 Goodwill 7,790,50 8,024,729 Intangable assets, net 2,955,40 1,566,23 1,566,23 1,566,23 1,566,23 1,680,245	Accounts receivable, net	,	653,104
Total current assets 35,070,381 16,887,632 Priperty and equipment 42,231,55 325,9487 Finance lease right-of-use assets, net 227,009 449,628 Operating lease right-of-use assets 2,030,073 2,082,300 Goodwill 7,990,55 8,024,729 Intensity 2,995,436 1,680,303 Strategic inventory 2,995,436 1,680,303 Other noncurrent assets 555,102 7,995,55 Total assets 5,562,324 1,580,606 Charrier to Millities 1,207,113 1,886,666 Accrued compensation and benefits 1,207,113 1,886,666 Accrued compensation and benefits 1,541,893 1,487,411 Deferred revenue 1,541,893 6,742,411 Observation Equilabilities 852,253	Inventory, net	1,333,880	1,485,986
Property and equipment, net 4,223,155 3,259,487 Finance lease right-of-use assets, net 207,300 4,46,288 Operating lease right-of-use assets 2,038,073 2,082,300 Goodwill 15,66,535 16,580,908 Intangible assets, net 15,66,534 16,869,482 Other noncurrent sets 5,55,190 779,555 Statagic inventory 2,995,436 1,686,482 Other noncurrent assets 5,55,190 79,751,405 Statagic inventory 5,65,633 4975,104 Statagic inventory 5,05,633 4,05,104 Accounts passed as the state of the state o	Prepaid expenses and other current assets	2,081,549	1,388,090
Finance lease right-of-use assets, net 227,209 449,628 Operating lease right-of-use assets 2,038,039 3,082,300 Goodwill 17,90,505 8,024,202 Intangible assets, net 15,662,324 16,580,633 Strategic inventory 2,995,436 1,686,632 Other noncurrent assets 555,109 779,953 Total assets 55,109 779,055 Total sets 5,207,13 1,886,666 Coursel fabilities 1,541,889 2,126,511 Accrued compensation and benefits 1,541,889 2,126,511 Accrued compensation and benefits 1,541,889 2,126,511 Accrued Liabilities 1,541,889 2,126,511 Accrued Liabilities 1,541,889 2,126,511 Accrued Liabilities 1,680,600 1,437,141 Defered revenue 9,808 2,607,000 Short-term finance lease liabilities 116,829 266,470 Short-term finance lease liabilities 1,808,606 7,372,00 Long-term finance lease liabilities 2,802,400 1,937,30 <td>Total current assets</td> <td> 35,070,381</td> <td>16,887,643</td>	Total current assets	 35,070,381	16,887,643
Operating lease right-of-use assets 2,083,073 2,082,300 Goodwill 7,790,595 8,024,729 Intangible assets, net 15,662,324 16,560,363 Other noncurent assets 2,995,436 779,953 Total asset 5,856,236 799,953 Total asset 8,856,236 9,875,100 Liabilities and Stockholders' Equity 8,120,711 1,868,666 Accounts payable 1,541,898 2,126,511 Account assets 1,131,998 1,437,411 Defered evenue 1,131,998 1,437,411 Current maturities of long-term debt 11,609 690,000 Current maturities of long-term debt 116,609 690,000 Short-term operating lease liabilities 116,609 7,372,009 Short-term finance lease liabilities 1,869,409 7,372,009 Long-term operating lease liabilities 2,807,009 7,372,009 Long-term finance lease liabilities 2,807,009 7,372,009 Long-term finance lease liabilities 2,807,009 1,808,009 Long-term finance lease liabilities	Property and equipment, net	4,223,155	3,259,487
Goodsell 7,90,955 8,042,729 Intangible assets, net 15,662,324 16,580,324 Strategic inventory 2,995,436 1,580,324 Other noncurrent assets 555,190 779,935 Total asset 56,562,323 49,751,045 Labilities and Stockholders' Equity 8 8,652,333 1,868,666 Current labilities 1,541,898 2,126,151 Accrued compasation and benefits 1,371,196 1,437,141 Accrued compasation and benefits 1,137,196 1,437,141 Accrued compassation and benefits 1,137,196 2,647,000 Accrued accompany and the series in the series of the serie	Finance lease right-of-use assets, net	227,209	449,628
Brangible assers, net 15,662,324 16,580,368 Strategic inventory 2,995,436 1,780,358 Other noncurrent assers 5,685,520 9,795,158 Total asset 5,685,523 9,795,108 Earlitities and Stockholders' Equity 8,120,711 1,868,666 Accounts payable 1,541,989 2,126,511 Accounts payable 1,541,989 2,126,511 Account compensation and benefits 1,541,989 2,126,511 Account disbilities 1,541,989 2,126,511 Account instituties of long-term debt — 9,800 Current maturities of long-term debt — 9,900 Short-term inance lease liabilities 116,629 69,000 Short-term operating lease liabilities 2,870,401 19,378,303 Long-term debt, ret 2,910,810 1,492,544 Long-term operating lease liabilities 2,910,810 1,492,544 Long-term operating lease liabilities 2,910,810 1,492,544 Long-term finance lease liabilities 2,820,820 1,282,520 Long-term finance lease liabilitie	Operating lease right-of-use assets	2,038,073	2,082,300
Strategic inventory 2,995,436 1,686.342 Other noncurrent assets 55,50 77,935 Total assets 68,562,363 9,497,1045 Liabilities and Stockholders' Equity 8 1,207,113 1,686,666 Accounts liabilities 1,247,131 1,686,666 Accured compensation and benefits 1,541,698 2,126,511 Accured liabilities 1,541,898 2,126,511 Deferred revene 1,541,898 2,126,511 Defered revene 1,62 699,000 Short-rem finance lease liabilities 36,233 96,434 Short-rem perating lease liabilities 38,233 96,434 Total current liabilities 38,233 96,343 Long-term finance lease liabilities 38,233 96,345 Long-term liabilities 18,693 4,679,48 Long-term liabilities 2,910,810 1,937,83 Long-term liabilities 38,243 1,508,28 Long-term liabilities 38,263 4,579,48 Long-term liabilities 2,910,810 1,942,54	Goodwill	7,790,595	8,024,729
Other noncurrent assets 555,190 779,935 Total assets 8 8,562,303 8 49,751,045 Labilities and Stockholders' Equity Formula bilities Accounds payable \$ 1,207,113 \$ 1,868,666 Accound compensation and benefits 1,514,989 2,126,511 Accound liabilities 1,137,196 1,437,141 Deferred revenue — — 9,808 Current maturities of long-term debt — 16,200 26,407 Short-term operating lease liabilities 116,829 266,470 Short-term operating lease liabilities 4,857,699 737,403 Long-term debt, net 2,067,904 19,378,935 Long-term debt, net 2,067,904 19,378,935 Long-term operating lease liabilities 2,076,904 19,378,935 Long-term operating lease liabilities 2,087,904 19,378,935 Derivative liabilities 2,22,387 11,285 Other long-term liabilities 2,22,387 12,565,34 Total current accounting and contingencies (Notes) 2,22,387 2,255,979 Total Liabilities	Intangible assets, net	15,662,324	16,580,963
Total assets 6.8562,363 9.8751,045 Libilities and Stockholders' Equity Cornent liabilities 3.1,207,113 \$ 1,868,666 Accounts payable \$ 1,207,113 \$ 1,868,666 Accrued compensation and benefits 1,541,848 2,126,511 Accrued liabilities 1,541,848 2,126,511 Deferred revene — 6 9,808 Current maturities of long-term debt 116,629 266,470 Short-term finance lease liabilities 116,629 266,470 Short-term operating lease liabilities 4,857,269 7,372,000 Long-term debt, net 2,070,941 19,378,935 Long-term poperating lease liabilities 1,809,50 1,402,544 Long-term poperating lease liabilities 2,910,41 1,9378,935 Long-term poperating lease liabilities 2,910,41 1,9378,935 Long-term poperating lease liabilities 2,910,41 1,9378,935 Comptenti liabilities 2,910,41 1,9378,935 Comptenti liabilities 2,920,41 1,925,44 Comptenti liabilities 2,920,41 1,920,44 <td>Strategic inventory</td> <td>2,995,436</td> <td>1,686,342</td>	Strategic inventory	2,995,436	1,686,342
Page Page	Other noncurrent assets	555,190	779,953
Current liabilities \$ 1,207,113 \$ 1,886,666 Accounds payable 1,541,898 2,126,511 Accound compensation and benefits 1,137,196 1,437,141 Accrued liabilities 1,137,196 1,437,141 Defered revenue ————————————————————————————————————	Total assets	\$ 68,562,363	\$ 49,751,045
Accounts payable \$ 1,207,113 \$ 1,868,666 Accound compensation and benefits 1,541,898 2,126,511 Accrued liabilities 1,137,196 1,437,141 Deferred revenue — 9,808 Current maturities of long-term debt — 699,000 Short-term finance lease liabilities 116,829 266,470 Short-term operating lease liabilities 854,233 964,434 Total current liabilities 4,857,269 7,372,030 Long-term debt, net 20,670,941 19,378,935 Long-term finance lease liabilities 20,670,941 19,378,935 Long-term finance lease liabilities 2,910,810 4,875,269 Long-term perating lease liabilities 2,910,810 1,492,544 Long-term liabilities 2,910,810 1,492,544 Other long-term liabilities 2,21,328 112,852 Total tabilities 3,826,444 2,855,790 Total tabilities 2,826,444 2,855,790 Total tabilities 3,826,444 2,855,790 Total tabilities 3,826,444	<u>Liabilities and Stockholders' Equity</u>	 	
Accrued compensation and benefits 1,541,898 2,126,511 Accrued liabilities 1,137,196 1,437,141 Deferred revenue – 9,808 Current maturities of long-term debt – 699,000 Short-term finance lease liabilities 116,829 266,470 Short-term operating lease liabilities 4,857,269 7,372,030 Cong-term debt, net 20,670,941 19,378,935 Long-term liabilities 20,670,941 19,378,935 Long-term operating lease liabilities 18,693 46,794 Long-term prinance lease liabilities 2,910,810 1,492,544 Derivative liabilities 222,387 121,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) 5 5 Stockholders' equity - - Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 - - 25,085,534 shares issued and outstanding at June 30, 2021 and 202, 202, 202, 202, 202, 202, 202, 202	Current liabilities		
Accrued liabilities 1,137,196 1,437,141 Deferred revenue — 9,888 Current maturities of long-term debt — 699,000 Short-term finance lease liabilities 116,829 266,470 Short-term operating lease liabilities 854,233 964,434 Total current liabilities 2,907,094 19,378,935 Long-term debt, net 2,907,094 19,378,935 Long-term perating lease liabilities 18,693 46,794 Long-term perating lease liabilities 2,910,810 1,492,544 Derivative liabilities 2,910,810 1,492,544 Derivative liabilities 222,387 112,852 Other long-term liabilities 28,826,444 28,559,790 Total liabilities 28,826,444 28,559,790 Committents and contingencies (Note 9) — — — Total liabilities 3,01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 382,703 250,855	Accounts payable	\$ 1,207,113	\$ 1,868,666
Deferred revenue — 9,808 Current maturities of long-term debt — 699,000 Short-term finance lease liabilities 116,829 266,470 Short-term operating lease liabilities 854,233 964,334 Total current liabilities 4,857,269 7,372,036 Long-term debt, net 20,670,941 19,378,935 Long-term inance lease liabilities 18,693 46,794 Long-term operating lease liabilities 2,910,810 1,492,544 Long-term operating lease liabilities 2,910,810 1,492,544 Derivative liabilities 222,387 112,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,709 Commitments and contingencies (Note 9) Terferred stock, 50.01 par value; 10,000,000 shares authorized; none issued and utstanding at June 30, 2021 and December 31, 2020 — — Common stock, 50.01 par value; 50,000,000 shares authorized; 38,270,250 and 382,703 25,085,534 December 31, 2020, respectively 382,703 25,085,534 Ad	Accrued compensation and benefits	1,541,898	2,126,511
Current maturities of long-term debt — 699,000 Short-term finance lease liabilities 116,829 266,470 Short-term operating lease liabilities 854,233 964,434 Total current liabilities 4,857,269 7,372,030 Long-term debt, net 20,670,941 19,378,935 Long-term finance lease liabilities 1,8693 46,794 Long-term operating lease liabilities 2,910,810 1,492,544 Derivative liabilities 2,213,87 112,682 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) 38,264,44 28,559,790 Stockholders' equity ————————————————————————————————————	Accrued liabilities	1,137,196	1,437,141
Short-term finance lease liabilities 116,829 266,470 Short-term operating lease liabilities 854,233 964,434 Total current liabilities 4,857,269 7,372,030 Long-term debt, net 20,670,941 19,378,935 Long-term finance lease liabilities 18,693 46,794 Long-term operating lease liabilities 2910,810 1,492,544 Derivative liabilities 222,387 112,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) 382,703 56,635 Stockholders' equity — — Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 382,703 250,855 December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (200,735,827) Accumulated other comprehensive income <th< td=""><td>Deferred revenue</td><td>_</td><td>9,808</td></th<>	Deferred revenue	_	9,808
Short-term operating lease liabilities 85,233 964,434 Total current liabilities 4,857,269 7,372,030 Long-term debt, net 20,670,941 19,378,935 Long-term finabilities 2,910,810 1,492,54 Long-term operating lease liabilities 222,337 11,255 Other long-term liabilities 222,337 115,635 Total liabilities 38,26444 28,559,790 Commitments and contingencies (Note 9) 8 5 Stockholders' equity - - Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 - - Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 382,703 250,855 25,085,534 shares issued and outstanding at June 30, 2021 and 382,703 250,855 December 31, 2020, respectively 382,703 250,855 Additional paid-in-capital 260,027,841 219,129,045 Accumulated deficit 222,672,979 (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total s	Current maturities of long-term debt	_	699,000
Total current liabilities 4,857,269 7,372,030 Long-term debt, net 20,670,941 19,378,935 Long-term finance lease liabilities 18,693 46,794 Long-term operating lease liabilities 2,910,810 1,492,544 Derivative liabilities 222,387 112,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 25,085,534 shares issued and outstanding at June 30, 2021 and 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Short-term finance lease liabilities	116,829	266,470
Long-term debt, net 20,670,941 19,378,935 Long-term finance lease liabilities 18,693 46,794 Long-term operating lease liabilities 2,910,810 1,492,544 Derivative liabilities 222,387 112,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) Terferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 25,085,534 shares issued and outstanding at June 30, 2021 and — — December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,799) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Short-term operating lease liabilities	854,233	964,434
Long-term finance lease liabilities 18,693 46,794 Long-term operating lease liabilities 2,910,810 1,492,544 Derivative liabilities 222,387 112,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) *** **Total representations of the preferred stockholders' equity *** **Total stockholders' equity *** **Total stockholders' equity *** **Total stockholders' equity *** **Total stockholders' equity \$**	Total current liabilities	 4,857,269	7,372,030
Long-term operating lease liabilities 2,910,810 1,492,544 Derivative liabilities 222,387 112,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and — — — 25,085,534 shares issued and outstanding at June 30, 2021 and 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Long-term debt, net	20,670,941	19,378,935
Derivative liabilities 222,387 112,852 Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 382,703 250,855 25,085,534 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Long-term finance lease liabilities	18,693	46,794
Other long-term liabilities 146,344 156,635 Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 —	Long-term operating lease liabilities	2,910,810	1,492,544
Total liabilities 28,826,444 28,559,790 Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 25,085,534 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (202,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Derivative liabilities	222,387	112,852
Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 25,085,534 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Other long-term liabilities	146,344	156,635
Stockholders' equity Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 50,000,000 shares authorized; 30,000,000 shares authorized; 30,000 shares authorized	Total liabilities	 28,826,444	28,559,790
Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 25,085,534 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Commitments and contingencies (Note 9)	 	
outstanding at June 30, 2021 and December 31, 2020 — — Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 50,85,534 shares issued and outstanding at June 30, 2021 and 382,703 250,855 December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Stockholders' equity		
Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and 382,703 250,855 25,085,534 shares issued and outstanding at June 30, 2021 and 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and		
25,085,534 shares issued and outstanding at June 30, 2021 and 382,703 250,855 December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	outstanding at June 30, 2021 and December 31, 2020	_	_
December 31, 2020, respectively 382,703 250,855 Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Common stock, \$0.01 par value; 50,000,000 shares authorized; 38,270,250 and		
Additional paid-in capital 260,027,841 219,129,045 Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255			
Accumulated deficit (222,672,979) (200,735,827) Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	December 31, 2020, respectively		
Accumulated other comprehensive income 1,998,354 2,547,182 Total stockholders' equity 39,735,919 21,191,255	Additional paid-in capital		
Total stockholders' equity 39,735,919 21,191,255	Accumulated deficit	(222,672,979)	(200,735,827)
	Accumulated other comprehensive income	1,998,354	2,547,182
Total liabilities and stockholders' equity \$ 68,562,363 \$ 49,751,045	Total stockholders' equity	39,735,919	21,191,255
	Total liabilities and stockholders' equity	\$ 68,562,363	\$ 49,751,045

OpGen, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

	Three months ended June 30,		une 30,	Six months ended June 30,				
		2021		2020		2021		2020
Revenue								
Product sales	\$	307,804	\$	601,304	\$	835,383	\$	968,237
Laboratory services		266,784		25,992		450,849		25,992
Collaboration revenue		237,027		561,089		355,099		811,089
Total revenue		811,615	-	1,188,385		1,641,331		1,805,318
Operating expenses	· · · · · · · · · · · · · · · · · · ·	_						
Cost of products sold		342,580		713,916		896,634		990,470
Cost of services		137,934		252,655		242,918		390,321
Research and development		2,859,590		2,979,025		5,673,081		4,196,581
General and administrative		2,692,255		2,491,571		5,355,912		4,193,019
Sales and marketing		802,549		1,044,032		1,701,801		1,326,309
Transaction costs		_		225,000		_		470,322
Impairment of right-of-use asset		115,218				170,714		_
Impairment of intangibles assets		_		_		_		750,596
Total operating expenses		6,950,126		7,706,199		14,041,060		12,317,618
Operating loss		(6,138,511)		(6,517,814)		(12,399,729)		(10,512,300)
Other (expense) income								
Gain on extinguishment of debt		259,353		_		259,353		_
Warrant inducement expense		_		_		(7,755,541)		_
Interest and other income (expense)		4,702		(5,656)		9,627		81,679
Interest expense		(1,198,169)		(1,044,891)		(2,363,151)		(1,083,158)
Foreign currency transaction (losses) gains		(915)		(289,788)		426,700		(293,664)
Change in fair value of derivative financial instruments		(13,021)		382,511		(114,411)		382,511
Total other (expense) income		(948,050)		(957,824)		(9,537,423)		(912,632)
Loss before income taxes		(7,086,561)		(7,475,638)		(21,937,152)		(11,424,932)
Provision for income taxes		_		_		_		_
Net loss	\$	(7,086,561)	\$	(7,475,638)	\$	(21,937,152)	\$	(11,424,932)
Net loss available to common stockholders	\$	(7,086,561)	\$	(7,475,638)	\$	(21,937,152)	\$	(11,424,932)
Net loss per common share - basic and diluted	\$	(0.19)	\$	(0.49)	\$	(0.65)	\$	(1.00)
Weighted average shares outstanding - basic and diluted		38,268,293		15,403,986		33,900,964		11,427,322
Net loss	\$	(7,086,561)	\$	(7,475,638)	\$	(21,937,152)	\$	(11,424,932)
Other comprehensive income (loss) - foreign currency								
translation		529,651		324,939		(548,828)		364,416
Comprehensive loss	\$	(6,556,910)	\$	(7,150,699)	\$	(22,485,980)	\$	(11,060,516)

OpGen: Oliver Schacht President and CEO Investor Relations @opgen.com

OpGen Press Contact:

Matthew Bretzius

FischTank Marketing and PR matt@fischtankpr.com

OpGen Investor Contact: Max Colbert **Edison Group**

mcolbert@edisongroup.com